Abstract:Since the U.S. Food and Drug Administration (FDA) granted emergency use authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has attracted broad attention from the scientific community to investors. When delivered intracellularly, mRNA has the ability to produce various therapeutic proteins, enabling the treatment of a variety of illnesses, including but not limited to infectious diseases, cancers, and genetic diseases. Accordingly, mRNA holds significant therapeutic potential and provides a promising means to target historically hard-to-treat diseases. Current clinical efforts harnessing mRNA-based technology are focused on vaccination, cancer immunotherapy, protein replacement therapy, and genome editing. The clinical translation of mRNA-based technology has been made possible by leveraging nanoparticle delivery methods. However, the application of mRNA for therapeutic purposes is still challenged by the need for specific, efficient, and safe delivery systems.This Account highlights key advances in designing and developing combinatorial synthetic lipid nanoparticles (LNPs) with distinct chemical structures and properties for in vitro and in vivo intracellular mRNA delivery. LNPs represent the most advanced nonviral nanoparticle delivery systems that have been extensively investigated for nucleic acid delivery. The aforementioned COVID-19 mRNA vaccines and one LNP-based small interfering RNA (siRNA) drug (ONPATTRO) have received clinical approval from the FDA, highlighting the success of synthetic ionizable lipids for in vivo nucleic acid delivery. In this Account, we first summarize the research efforts from our group on the development of bioreducible and biodegradable LNPs by leveraging the combinatorial chemistry strategy, such as the Michael addition reaction, which allows us to easily generate a large set of lipidoids with diverse chemical structures. Next, we discuss the utilization of a library screening strategy to identify optimal LNPs for targeted mRNA delivery and showcase the applications of the optimized LNPs in cell engineering and genome editing. Finally, we outline key challenges to the clinical translation of mRNA-based therapies and propose an outlook for future directions of the chemical design and optimization of LNPs to improve the safety and specificity of mRNA drugs. We hope this Account provides insight into the rational design of LNPs for facilitating the development of mRNA therapeutics, a transformative technology that promises to revolutionize future medicine.

Lung-Specific mRNA Delivery Enabled by Sulfonium Lipid Nanoparticles

One‐Component Cationic Lipids for Systemic Mrna Delivery to Splenic T Cells

Branched‐Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

Strategies for Organ-Targeted mRNA Delivery by Lipid Nanoparticles.

Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation

Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments

Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery

Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery

Recent Advances in Lipid Nanoparticles for Delivery of mRNA

Zwitterionic Polymer-Functionalized Lipid Nanoparticles for the Nebulized Delivery of mRNA

Development and applications of mRNA treatment based on lipid nanoparticles

Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation.

An overview of lipid constituents in lipid nanoparticle mRNA delivery systems

Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver

Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics

Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing

Enhancing spleen-targeted mRNA delivery with branched biodegradable tails in lipid nanoparticles

Cationic Lipid Pairs Enhance Liver-to-Lung Tropism of Lipid Nanoparticles for In Vivo mRNA Delivery

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis

Development of Organ Targeting Lipid Nanoparticles with Low Immunogenicity and Their Application in the Treatment of Pulmonary Fibrosis

Helper Lipid-Enhanced mRNA Delivery for Treating Metabolic Dysfunction-Associated Fatty Liver Disease